<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">sibmed</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский научный медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Сибирский научный медицинский журнал</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2410-2512</issn><issn pub-type="epub">2410-2520</issn><publisher><publisher-name>ИЦиГ СО РАН</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18699/SSMJ20230306</article-id><article-id custom-type="elpub" pub-id-type="custom">sibmed-1106</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕДИКО-БИОЛОГИЧЕСКИЕ НАУКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>BIOMEDICINE</subject></subj-group></article-categories><title-group><article-title>Влияние мевалоната, золедроната и БЦЖ-индукции на фенотип моноцитов/макрофагов</article-title><trans-title-group xml:lang="en"><trans-title>Effect of mevalonate, zoledronate and BCG on monocyte/macrophage phenotype</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4897-8676</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лыков</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Lykov</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лыков Александр Петрович, к.м.н.</p><p>630040, г. Новосибирск, ул. Охотская, 81а</p></bio><bio xml:lang="en"><p>Alexander P. Lykov, candidate of medical sciences</p><p>630040, Novosibirsk, Okhotskaya str., 81a</p></bio><email xlink:type="simple">aplykov2@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3481-3793</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белогородцев</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Belogorodtsev</surname><given-names>S. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Белогородцев Сергей Николаевич, к.м.н.</p><p>630040, г. Новосибирск, ул. Охотская, 81а</p></bio><bio xml:lang="en"><p>Sergei N. Belogorodtsev, candidate of medical sciences</p><p>630040, Novosibirsk, Okhotskaya str., 81a</p></bio><email xlink:type="simple">s.belogorodtsev@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2724-9546</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Немкова</surname><given-names>Е. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Nemkova</surname><given-names>E. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Немкова Елизавета Кирилловна</p><p>630040, г. Новосибирск, ул. Охотская, 81а</p></bio><bio xml:lang="en"><p>Elizaveta K. Nemkova</p><p>630040, Novosibirsk, Okhotskaya str., 81a</p></bio><email xlink:type="simple">elizaveta.nemkova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1776-0466</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ветлугина</surname><given-names>А.</given-names></name><name name-style="western" xml:lang="en"><surname>Vetlugina</surname><given-names>A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ветлугина Анна</p><p>630040, г. Новосибирск, ул. Охотская, 81а</p></bio><bio xml:lang="en"><p>Anna Vetlugina</p><p>630040, Novosibirsk, Okhotskaya str., 81a</p></bio><email xlink:type="simple">morpho.peleides.1997@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5313-7594</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Терехова</surname><given-names>Т. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Terekhova</surname><given-names>T. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Терехова Татьяна Михайловна</p><p>630040, г. Новосибирск, ул. Охотская, 81а</p></bio><bio xml:lang="en"><p>Tatjana M. Terekhova</p><p>630040, Novosibirsk, Okhotskaya str., 81a</p></bio><email xlink:type="simple">t.terekhova98@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3036-9795</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шварц</surname><given-names>Я. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Schwartz</surname><given-names>Ya. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шварц Яков Шмульевич, д.м.н.</p><p>630040, г. Новосибирск, ул. Охотская, 81а</p></bio><bio xml:lang="en"><p>Yakov Sh. Schwartz, doctor of medical sciences</p><p>630040, Novosibirsk, Okhotskaya str., 81a</p></bio><email xlink:type="simple">yshschwartz@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Новосибирский НИИ туберкулеза Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk Tuberculosis Research Institute of Minzdrav of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>23</day><month>06</month><year>2023</year></pub-date><volume>43</volume><issue>3</issue><elocation-id>57−63</elocation-id><permissions><copyright-statement>Copyright &amp;#x00A9; Лыков А.П., Белогородцев С.Н., Немкова Е.К., Ветлугина А., Терехова Т.М., Шварц Я.Ш., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Лыков А.П., Белогородцев С.Н., Немкова Е.К., Ветлугина А., Терехова Т.М., Шварц Я.Ш.</copyright-holder><copyright-holder xml:lang="en">Lykov A.P., Belogorodtsev S.N., Nemkova E.K., Vetlugina A., Terekhova T.M., Schwartz Y.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://sibmed.elpub.ru/jour/article/view/1106">https://sibmed.elpub.ru/jour/article/view/1106</self-uri><abstract><p>Клетки врожденного иммунитета, в основном моноциты/макрофаги, при первичной встрече с патогеном формируют долговременную неспецифическую иммунологическую память, так называемый тренированный иммунитет. В его образовании важная роль отводится метаболитам мевалонатного пути. Целью исследования было изучение влияния модуляторов мевалонатного пути, мевалоната и золедроната, на формирование тренированного иммунитета в моноцитах/макрофагах человека и животных.Материал и методы. Использованы моноцитоподобные клеточные линии человека THP-1 и U-937, перитонеальные макрофаги мышей BALB/c. Тренированный иммунитет индуцировали in vitro инкубацией клеток THP-1 и U-937 в течение 24 и 72 часов с инактивированными микобактериями вакцинального штамма БЦЖ, а in vivo – внутрибрюшинным введением БЦЖ мышам BALB/c с выделением перитонеальных макрофагов на 7-е сутки после инфицирования (лаг-фаза). Гиперреактивность клеток оценивали ответом на второй стимул бактериальным липополисахаридом (ЛПС) и меваланатом, золедранатом в присутствии или в отсутствие ЛПС. В кондиционированных средах от клеток оценивали уровень лактата, цитокинов (IL-1β, TNF-α, IL-10), оксида азота и глюкозы.Результаты и их обсуждение. Обнаружено, что моноцитоподобные клеточные линии THP-1 и U-937 по-разному отвечают продукцией цитокинов, лактата и потреблением глюкозы на БЦЖ-стимул при наличии или отсутствии лаг-фазы. Мевалонат и золедронат сами по себе или в сочетании с ЛПС также по-разному стимулируют секрецию цитокинов. Наличие лаг-фазы для моноцитоподобных клеток человека существенно для уровня продукции цитокинов и потребления глюкозы. Показано, что перитонеальные макрофаги усиливают выброс провоспалительных цитокинов в ответ на ЛПС, мевалонат и золедронат.Заключение. Мевалонат и золедронат индуцируют в моноцитах/макрофагах тренированный иммунитет.</p></abstract><trans-abstract xml:lang="en"><p>Cells of innate immunity, mainly monocytes/macrophages, form a long-term nonspecific immunological memory during the initial encounter with the pathogen, the so-called trained immunity. Mevalonate pathway metabolites play an important role in the formation of trained immunity. The aim of this investigation was to study the effect of modulators of mevalonate pathway, mevalonate and zoledronate, on the formation of trained immunity in human and animal monocytes/ macrophages.Material and methods. Human monocyte-like cell lines THP-1 and U-937, peritoneal macrophages of BALB/c mice were used. Trained immunity was induced in vitro by incubation of THP-1 and U-937 monocyte-like cell lines for 24 and 72 hours with inactivated Mycobacteria of BCG vaccine strain, and in vivo by intraperitoneal administration of BCG to BALB/c mice with isolation of peritoneal macrophages on day 7 after infection (lag phase). Cell hyperreactivity was assessed by response to a second stimulus with bacterial lipopolysaccharide (LPS) and mevalonate, zoledranate in the presence or absence of LPS. Lactate, cytokine (IL-1β, TNF-α, IL-10), nitric oxide and glucose level was measured in conditioned media from cells.Results and discussion. The study showed that monocyte-like cell lines THP-1 and U-937 responded differently by cytokine production, lactate, and glucose consumption to BCG stimulus in the presence or absence of lag phase. Mevalonate and zoledronate alone or in combination with LPS also stimulated cytokine production in different ways. The presence of lag phase for human monocyte-like cells is essential for the level of cytokine production and glucose consumption. Peritoneal macrophages have been shown to enhance pro-inflammatory cytokine production in response to LPS, mevalonate, and zoledronate.Conclusions. Mevalonate and zoledronate induce trained immunity in monocytes/macrophages.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>THP-1</kwd><kwd>U-937</kwd><kwd>перитонеальные макрофаги</kwd><kwd>вакцина БЦЖ</kwd><kwd>липополисахарид</kwd><kwd>мевалонат</kwd><kwd>золедронат</kwd><kwd>лактат</kwd><kwd>цитокины</kwd><kwd>оксид азота</kwd><kwd>потребление глюкозы</kwd><kwd>тренированный иммунитет</kwd></kwd-group><kwd-group xml:lang="en"><kwd>THP-1</kwd><kwd>U-937</kwd><kwd>peritoneal macrophages</kwd><kwd>BCG vaccine</kwd><kwd>lipopolysaccharide</kwd><kwd>mevalonate</kwd><kwd>zoledronate</kwd><kwd>lactate</kwd><kwd>cytokines</kwd><kwd>nitric oxide</kwd><kwd>glucose consumption</kwd><kwd>trained immunity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bekkering S., Domínguez-Andrés J., Joosten L.A.B., Riksen N.P., Netea M.G. Trained Immunity: Reprogramming Innate Immunity in Health and Disease. Annu. Rrev. Imunol. 2021;39:667–693. doi: 10.1146/annurev-immunol-102119-073855</mixed-citation><mixed-citation xml:lang="en">Bekkering S., Domínguez-Andrés J., Joosten L.A.B., Riksen N.P., Netea M.G. Trained Immunity: Reprogramming Innate Immunity in Health and Disease. Annu. Rrev. Imunol. 2021;39:667–693. doi: 10.1146/annurev-immunol-102119-073855</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bekkering S., Blok B.A., Joosten L.A.B., Riksen N.P., van Crevel R., Netea M.G. In vitro experimental model of trained innate immunity in human primary monocytes. Clin. Vaccine Immunol. 2016;23(12):926–933. doi: 10.1128/CVI.00349-16</mixed-citation><mixed-citation xml:lang="en">Bekkering S., Blok B.A., Joosten L.A.B., Riksen N.P., van Crevel R., Netea M.G. In vitro experimental model of trained innate immunity in human primary monocytes. Clin. Vaccine Immunol. 2016;23(12):926–933. doi: 10.1128/CVI.00349-16</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng S.C., Quintin J., Cramer R.A., Shepardson K.M., Saeed S., Kumar V., Giamarellos-Bourboulis E.J., Martens J.H.A., Rao N.A, Aghajanirefah A., … Netea M.G. mTOR/HIF1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345(6204):1250684. doi: 10.1126/science.1250684</mixed-citation><mixed-citation xml:lang="en">Cheng S.C., Quintin J., Cramer R.A., Shepardson K.M., Saeed S., Kumar V., Giamarellos-Bourboulis E.J., Martens J.H.A., Rao N.A, Aghajanirefah A., … Netea M.G. mTOR/HIF1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345(6204):1250684. doi: 10.1126/science.1250684</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sohrabi Y., Sonntag G.V.H., Braun L.C., Lagache S.M.M., Liebmann M., Klotz L., Godfrey R., Kahles F., Waltenberger J., Findeisen H.M. LXR activation induces a proinflammatory trained innate immunity- phenotype in human monocytes. Front. Immunol. 2020;11:353. doi: 10.3389/fimmu.2020.00353</mixed-citation><mixed-citation xml:lang="en">Sohrabi Y., Sonntag G.V.H., Braun L.C., Lagache S.M.M., Liebmann M., Klotz L., Godfrey R., Kahles F., Waltenberger J., Findeisen H.M. LXR activation induces a proinflammatory trained innate immunity- phenotype in human monocytes. Front. Immunol. 2020;11:353. doi: 10.3389/fimmu.2020.00353</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mulder W.J.M., Ochando J., Joosten L.A.B., Fayad Z.A., Netea M.G. Therapeutic targeting of trained immunity. Nat. Rev. Drug Discov. 2019;18(7):553–566. doi: 10.1038/s41573-019-0025-4</mixed-citation><mixed-citation xml:lang="en">Mulder W.J.M., Ochando J., Joosten L.A.B., Fayad Z.A., Netea M.G. Therapeutic targeting of trained immunity. Nat. Rev. Drug Discov. 2019;18(7):553–566. doi: 10.1038/s41573-019-0025-4</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Palgen J.L., Feraoun Y., Dzangué-Tchoupou G., Joly C., Martinon F., le Grand R., Beignon A.S. Optimize prime/boost vaccine strategies: trained immunity as a new player in the game. Front. Immunol. 2021;12: 612747. doi: 10.3389/fimmu.2021.612747</mixed-citation><mixed-citation xml:lang="en">Palgen J.L., Feraoun Y., Dzangué-Tchoupou G., Joly C., Martinon F., le Grand R., Beignon A.S. Optimize prime/boost vaccine strategies: trained immunity as a new player in the game. Front. Immunol. 2021;12: 612747. doi: 10.3389/fimmu.2021.612747</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mourits V.P., Wijkmans J.C., Joosten L.A., Netea M.G. Trained immunity as a novel therapeutic strategy. Curr. Opin. Pharmacol. 2018;41:52–58. doi: 10.1016/j.coph.2018.04.007</mixed-citation><mixed-citation xml:lang="en">Mourits V.P., Wijkmans J.C., Joosten L.A., Netea M.G. Trained immunity as a novel therapeutic strategy. Curr. Opin. Pharmacol. 2018;41:52–58. doi: 10.1016/j.coph.2018.04.007</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tercan H., Riksen N.P., Joosten L.A.B., Netea M.G., Bekkering S. Trained immunity: long-term adaptation in innate immune responses. Arterioscler. Thromb. Vasc. Biol. 2021;41(1):55–61. doi: 10.1161/ATVBAHA.120.314212</mixed-citation><mixed-citation xml:lang="en">Tercan H., Riksen N.P., Joosten L.A.B., Netea M.G., Bekkering S. Trained immunity: long-term adaptation in innate immune responses. Arterioscler. Thromb. Vasc. Biol. 2021;41(1):55–61. doi: 10.1161/ATVBAHA.120.314212</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bekkering S., Arts R.J.W., Novakovic B., Kourtzelis I., van der Heijden C.D.C.C., Li Y., Popa C.D., Ter Horst R., van Tuijl J., Netea-Maier R.T., … Netea M.G. Metabolic induction of trained immunity through the mevalonate pathway. Cell. 2018;172(1-2):135–146. doi: 10.1016/j.cell.2017.11.025</mixed-citation><mixed-citation xml:lang="en">Bekkering S., Arts R.J.W., Novakovic B., Kourtzelis I., van der Heijden C.D.C.C., Li Y., Popa C.D., Ter Horst R., van Tuijl J., Netea-Maier R.T., … Netea M.G. Metabolic induction of trained immunity through the mevalonate pathway. Cell. 2018;172(1-2):135–146. doi: 10.1016/j.cell.2017.11.025</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hoefert S., Hoefert C.S., Albert M., Munz A., Grimm M., Northoff H., Reinert S., Alexander D. Zoledronate but not denosumab suppresses macrophagic differentiation of THP-1 cells. An aetiologic model of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clin. Oral Investig. 2015;19(6):1307–1318. doi: 10.1007/s00784-014-1358-3</mixed-citation><mixed-citation xml:lang="en">Hoefert S., Hoefert C.S., Albert M., Munz A., Grimm M., Northoff H., Reinert S., Alexander D. Zoledronate but not denosumab suppresses macrophagic differentiation of THP-1 cells. An aetiologic model of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clin. Oral Investig. 2015;19(6):1307–1318. doi: 10.1007/s00784-014-1358-3</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Keating S.T., Groh L., van der Heijden C.D., Rodriguez H., dos Santos J.C., Fanucchi S., Okabe J., Kaipananickal H., van Puffelen J.H., Helder L., … Riksen N.P. The set7 lysine methyltransferase regulates plasticity in oxidative phosphorylation necessary for trained immunity induced by b-glucan. Cell Rep. 2020;31(3):107548. doi: 10.1016/j.celrep.2020.107548</mixed-citation><mixed-citation xml:lang="en">Keating S.T., Groh L., van der Heijden C.D., Rodriguez H., dos Santos J.C., Fanucchi S., Okabe J., Kaipananickal H., van Puffelen J.H., Helder L., … Riksen N.P. The set7 lysine methyltransferase regulates plasticity in oxidative phosphorylation necessary for trained immunity induced by b-glucan. Cell Rep. 2020;31(3):107548. doi: 10.1016/j.celrep.2020.107548</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Drummer C. 4th, Saaoud F., Shao Y., Sun Y., Xu K., Lu Y., Ni D., Atar D., Jiang X., Wang H., Yang X. Trained immunity and reactivity of macrophages and endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2021;41(3): 1032–1046. doi: 10.1161/ATVBAHA.120.315452</mixed-citation><mixed-citation xml:lang="en">Drummer C. 4th, Saaoud F., Shao Y., Sun Y., Xu K., Lu Y., Ni D., Atar D., Jiang X., Wang H., Yang X. Trained immunity and reactivity of macrophages and endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2021;41(3): 1032–1046. doi: 10.1161/ATVBAHA.120.315452</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Gruenbacher G., Thurnher M. Mevalonate metabolism in cancer stemness and trained immunity. Front Oncol. 2018;8:394. doi: 10.3389/fonc.2018.00394</mixed-citation><mixed-citation xml:lang="en">Gruenbacher G., Thurnher M. Mevalonate metabolism in cancer stemness and trained immunity. Front Oncol. 2018;8:394. doi: 10.3389/fonc.2018.00394</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wolf A.M., Rumpold H., Tilg H., Gastl G., Gunsilius E., Wolf D. The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica. 2006;91(9):1165–1171.</mixed-citation><mixed-citation xml:lang="en">Wolf A.M., Rumpold H., Tilg H., Gastl G., Gunsilius E., Wolf D. The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica. 2006;91(9):1165–1171.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Patntirapong S., Poolgesorn M. Alteration of macrophage viability, differentiation, and function by bisphosphonates. Oral Dis. 2018;24(7):1294–1302. doi: 10.1111/odi.1290</mixed-citation><mixed-citation xml:lang="en">Patntirapong S., Poolgesorn M. Alteration of macrophage viability, differentiation, and function by bisphosphonates. Oral Dis. 2018;24(7):1294–1302. doi: 10.1111/odi.1290</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
